期刊文献+

Bcl-2 siRNA增强HepG2细胞对5-氟尿嘧啶敏感性 被引量:1

Bcl-2 siRNA Increased Sensitivity to 5-Fluorouracil in HepG2 Cells
下载PDF
导出
摘要 目的观察Bcl-2 siRNA对人类肝癌细胞HepG2 5-氟尿嘧啶(5-FU)敏感性的影响。方法Bcl-2 siRNA表达载体构建并稳定转染至肝癌细胞HepG2中,用G418筛选稳定的阳性细胞克隆。用RT-PCR检测Bcl-2 mRNA水平,免疫荧光检测目的基因Bcl-2蛋白水平的表达。用131、30、1300和13 000 mg/L 5-FU处理稳定转染细胞,用MTT观察细胞对药物敏感性的影响,用流式细胞术观察细胞凋亡情况。Western blot检测Bcl-2和Bax蛋白水平。结果5-FU处理细胞24 h,Bcl-2 siRNA转染组的细胞生长抑制率明显高于阴性载体转染组和正常细胞;Bcl-2 siRNA转染组细胞凋亡率高于正常细胞和阴性载体转染组;在Bcl-2表达下调时,Bax蛋白表达水平不变。结论siRNA下调目的基因Bcl-2能增强人类肝癌细胞HepG2对5-FU的敏感性;HepG2细胞对5-FU的敏感性增强与Bax/Bcl-2的比例增高有关。 Objective To investigate the changes of sensitivity to 5 - fluorouracil (5 - FU)in Bcl- 2 siRNA transfected Hepg2 cells. Method Bcl - 2 siRNA expression vector were constructed and stably transfected into HepG2 cells. RT- PCR and Immunofluorescence were used to detect the target gene expression. Westem Blotting was used to detect Bcl - 2, Bax expressiom. Drug sensitivity of the cells to 5 - fluorouracil were analyzed with MTT and flow cytometry. Results MTT results showed that Bcl - 2 transfectants had a higher cell inhibition rate than negative vector or untreated cells after treated withl3, 130, 1 300, 13 000 mg/L 5 - FU; Moreover, Flow cytometry results demonstrated that Bcl - 2 siRNA cells had increased apoptosis rate compared with negative siRNA or untreated cell; The protein expression of Bax had no change when Bcl - 2 protein was reduced. Conclusion siRNA targeting Bcl - 2 gene can specifically down - regulate Bcl - 2 expression, increased Bax/Bcl - 2 ratio expression which lead to increase cell spontaneous apoptosis and sensitize cells to 5 - FU.
出处 《南华大学学报(医学版)》 2007年第4期503-506,共4页 Journal of Nanhua University(Medical Edition)
关键词 BCL-2 RNA干扰 HEPG2细胞 5-氟尿嘧啶 Bcl - 2 RNA interference HepG2 cells 5 - FU
  • 相关文献

参考文献16

  • 1Jacobson MD, Bume JF, King MP, et al. Bcl - 2 blocks apoptosis in ceils lacking mitochondrial DNA[J]. Nature, 1993,361 : 365 - 369.
  • 2Lauren Seiple, Pawel Jaruga, Miral Dizdaroglu, et al. Stivers linking uracil base excision repair and 5 - fluorouracil to:deity in yeast [J]. Nucleic Acids Reseal,ch,2006,34:140 - 151.
  • 3Boise LH, Gonzalez - Garcia M, Postema CE, et al. Bcl - x, a bcl - 2 - related gene that fianctions as a dominant regulator of apoptotic cell death [J]. Cell, 1993,74:597 - 608.
  • 4Fire A, Xu SQ, Montgomery MK, et al. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans [J] .Nature,1998,391(6669) :806 - 811.
  • 5Brummelkamp HR, Bemards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells [ J ]. Science, 2002,296 : 550 - 553.
  • 6Sui GC, Christina SH, Affar Ell, et al. DNA vector - based RNAi technology to suppress gene expression in mammalian cells[J]. Proc Natl Acad Sci USA,2002,99:515 - 520.
  • 7Yeh KH, Cheng AL. Recent advances in therapy for gastric cancer [J]. Fonnos ned Assoc, 2004,103(3): 171 - 185.
  • 8Kukk E, Lymboussaki A, Taira S, et al. VEGF - C receptor binding and pattern of expression with VEGFR - 3 suggests a role in lymphatic vascular development [J]. Devdopment, 1996, 122:3829 - 3837.
  • 9Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF- D) is a ligand for the tyrosine kinases VEGF receptor 2 (FLK1) and VEGF receptor 3 (Flt4)[J]. Proc Natl Acad Sci USA, 1998,95 : 548 - 553.
  • 10Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF- B) binds to VEGF receptor- 1 and regulates plasminogen activator activity in endothelial cells [ J ]. Proc Natl Acad Sci USA, 1998,95:11709- 11714.

同被引文献21

  • 1Mark F van Delft,David CS Huang.How the Bcl-2 family of proteins interact to regulate apoptosis[J].Cell Research,2006,16(2):203-213. 被引量:39
  • 2Tsujmoto Y, Gorham J , Croce CM, et al. The t (14,18)chromo- some translocations involved in B - cell neuoplasms result from mis- takes in VDJ joining [ J ]. Science , 1985,229 (4720) : 1390 - 1393.
  • 3Tortora G, Caputo R, Damiano V, et al. Combined targeted inhi- bition of bcl - 2, bcl - xl, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity [ J ]. Clin Cancer Res, 2003,9 ( 2 ) : 866 - 871.
  • 4Smith SR, Jin F, Joshi I. Enhanced efficacy of therapy with anti- sense BCL - 2 oligonucleotides plus anti - CD20 monoclonal antibody in scid mouse/human lymphoma xenografts [ J ]. Mol Cancer Ther,2004,3 ( 12 ) : 1693 - 1699.
  • 5Waters JS, Webb A, Cunningham D,et al. Phase I clinical and pharmacokinetic study of Bcl - 2 antisense oligonucleotide therapy in patients with non - Hodgkin's lymphoma [ J ]. J Clin Oncol, 2000,18(9) :1812 - 1823.
  • 6Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodyna- mic studies of G3139, a Bcl- 2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leu- kemia [ J ]. Blood ,2003,101 ( 2 ) :425 - 432.
  • 7Waters JS, Webb A, Curmingham D, et al. Phase I clinical and pharmacokinetic study of bcl - 2 antisense oligonucleotide therapy in patients with non - Hodgkin's lymphoma [ J ]. J Clin Oncol, 2000,18(9) :1812 - 1823.
  • 8Chi KN, Gleave ME, Klasa R, et al. A phase I dose -finding study of combined treatment with an antisense Bcl - 2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone -refractory prostate cancer[ J]. Clin Cancer Res,2001, 7 (12) :3920 - 3927.
  • 9Tolcher AW. Preliminary phase I results of G3139 ( bcl - 2 anti- sense oligonucleotide) therapy in combination with docetaxel in hormone - refractory prostate cancer [ J]. Semin Oneol, 2001,28 (4 Suppl 15) :67 -70.
  • 10Toeher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic and biological correlative study of oblimersen sodium and docetaxel in patients with hormone refractory prostate cancer [ J ]. Clin Cancer Res, 2005,11 (10) :3854 - 3861.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部